MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to coverage, PDL composition, or utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff.

Members Present: Cathy Zehrung, RPh; David Pass, MD; Phillip Levine, PhD; Stacy Ramirez, PharmD; William Origer, MD
Members Present by Phone: Joshua Bishop, PharmD; Tracy Klein, FNP; William Nunley, MD
Staff Present: Kathy Ketchum, RPh, MPA:HA; Megan Herink PharmD, BCPS; Richard Holsapple, RPh; Roger Citron, RPh; Ted Williams, PharmD; Trevor Douglass, DC, MPH; Valerie Smith
Staff Present by Phone: Kathy Sentena, PharmD
Audience: Jenny Blackham (Lilly); Diana Dills; Carol Choutka (Natl. MS Society); Jason Parks (ACSCAN); Bruce Dudley; Don Stetcher (Novartis); Mike Whitenak (lilly); Debbie McCazel; Kristina Harmach (BMS); Danielle Sobel (OMA); Barry Benson (Merck); Jim Gardner (PhRMA); Tzeli Triantafillon (VII); Jacob Owings (OSU COP); Bob Snediker (J&J); Tim Peterson (OSU COP); Brendon Biustein (OSU COP); Sheila Albeke (OSU COP); Lorren Sandt (Caring Ambassadors); Bill Struyk (J&J); Kim Lanbmeier (Otsuka); Lori Howarth; Deborah Crawford; Trish Mcdaid O'Neil; Dana Garet; Nancy Jodoin (Otsuka); Annie Ogotulak (Abbvie); Steve Hall; Bob Gustafson (Lundbeck); Bruce Smith (GSK); Paul Barham (NovoNordisk); Bruce Howard (Acorda); Shane Hall (Purdue); Michael Estos (Pfizer); Art Saig (Pfizer); Darren Coffman (HERC); Steve Isaki (Sunovion); John Goddard; Scott Goldfarb; Madalo Malin; Kathy Kirk (OPMC); Caryl McKesin (Western Oregon Advanced Health); Cat Linvingston (HERC)

I. CALL TO ORDER
   a. The meeting was called to order at approximately 1pm.
   b. Mr. Citron reported there are no new conflicts of interest to declare.
   c. The January 31, 3012 meeting minutes were reviewed.

ACTION: Approved as is.

II. DUR ACTIVITIES
   a. Mr. Holsapple presented the ProDUR Report.

ACTION: The Committee recommended discontinuing to allow CC-7 “Medically Appropriate” as an override code for early refills.
   b. Dr. Williams presented the RetroDUR Report.
   c. Mr. Citron presented the Quarterly Utilization Reports.
   d. Dr. Sentena presented the Oregon State Drug Review The Future of Newer Obesity Medication.

*Agenda items will be discussed by Committee members for the purpose of making recommendations to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9)
III. HERC COVERAGE GUIDANCE

Cat Livingston and Darren Coffman presented HERC coverage guidance on High Cost Marginal Benefit. Public comment was presented by: BJ Cavnor with NW Patient Education Network (written comment); Carol Choutka with the National MS Society; Deborah Crawford with Accorda Therapeutics; Jason Parks with the American Cancer Society; Jim Gardner with Gardner & Gardner Law Firm on behalf of PhRMA (written); and Lorren Sandt with Caring Ambassadors Foundation (written).

**ACTION:** The Committee recommended forming a Sub-Committee that will review High Cost Marginal Benefit drugs and report back to the P&T Committee.

IV. NEW BUSINESS

a. Dr. Williams presented a drug use evaluation on tapentadol recommending it be added to the High Dose Opioid PA Criteria, apply quantity limits consistent with PA Criteria, package insert and table optimization, and not grandfather patients currently receiving tapentadol.

**ACTION:** All in favor.

b. Ms. Ketchum presented a drug use evaluation on Colony Stimulating Factor Use in Patients with Hepatitis C recommending no further action is needed.

**ACTION:** All in favor.

c. Ms. Ketchum presented a drug use evaluation on Intramuscular Antipsychotics recommending OHA continues to allow billing of IM antipsychotics via drug claims, ensure professional claims and drug claims are reimbursed at the same but lowest rate, and consider engaging pharmacists via RetroDUR to evaluate patients for conversion to oral antipsychotics.

**ACTION:** All in favor.

d. Dr. Sentena presented a new drug evaluation on apixaban within the Anticoagulant Abbreviated drug class recommending making apixaban, rivaroxaban and dabigatran non-preferred with PA criteria to ensure appropriate use. Diana Dill with Pfizer presented public comment on apixaban. Steve Hall with Behringer Ingelheim presented public comment on dabigitran. Bob Sneticker with J&J/Janssen presented public comment on Xarelto.

**ACTION:** After Executive Session, all in favor.

e. Dr. Herink presented a new drug evaluation on tofacitinib within the Targeted Immune Modulators drug class recommending no changes be made to previous status of TIMS on the current PDL, but evaluate costs in Executive Session, Update the PA criteria to include the new indication of ulcerative colitis for adalimumab, reserve use of tofacitinib for patients who have tried another standard-of-care medications, and include tofacitinib in current TIMS PA criteria and evaluate comparative costs in Executive Session. Arti Baig with Pfizer presented public comment on tilfacitinib.

**ACTION:** After Executive Session, all in favor.

f. Dr. Herink presented a new drug evaluation on linaclotide recommending using the Exclude List PA criteria for linaclotide since IBS and constipation are below the OHP line of covered diagnoses. No PDL changes needed.

**ACTION:** After Executive Session, all in favor.

g. Dr. Herink presented drug class scans recommending:
   1. Topical Analgesics - no further research or review.

**ACTION:** After Executive Session, all in favor.

2. Topical Steroids - no further research or review and make desonide cream and ointment and alclometasone cream non-preferred, grandfathering current patients using these medications.

**ACTION:** After Executive Session, all in favor.

*Agenda items will be discussed by Committee members for the purpose of making recommendations to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9)*
3. Antifungals - no further research or review and code Oravig® as non-preferred since it is not rebatable.

*ACTION: After Executive Session, all in favor.

4. Topical Antifungals - no further research or review.

*ACTION: After Executive Session, all in favor.

V. The meeting was adjourned at approximately 4:30pm.

*Agenda items will be discussed by Committee members for the purpose of making recommendations to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9)